The next TPMRC will be held virtually on Friday November 10, 17, & 24, 2023 at 1200-1400 ET
There are no logo item. Please add some logo Item
Jump to a specific Day
Fri., Nov. 5 (Brain Injury)
Fri., Nov. 12 (SCI)
Sat., Nov. 13 (ALS/MS & Cancer)
Friday, November 5 (Brain Injury)
1200-1205
Introduction
Chantal Vaidyanath
1205-1225
Neuroradiolgy & TBI Controversies
Gordon Cheung
Brain SPECT is not a new imaging technique, nor is it considered an advanced neurodiagnostic tool, as some suggest. Brain SPECT originated in the
70’s for evaluation of strokes, seizures and brain tumours and was established in the early 80’s for studying dementia, head trauma, and
neuropsychiatric diseases. It is an old imaging technique that never lived up to its hype. Despite all this promise and interest, brain SPECT never
quite advanced to the levels that were anticipated, and it soon started to fizzle out. In the early 2000s, the market moved on, and interest shifted
to new modalities, like PET and fMRI. Today, the overall brain SPECT procedure volume accounts for less than 1% of all nuclear medicine studies (US
market). Although some may believe in a SPECT revival for TBI due to quantitative analysis, the issues of non-specificity, lack of a gold
standard, unknown false positivity rate (likely high) etc., are still present.
At the end of this session, participants will be able to:
Identify objective imaging studies for TBI
Assess if SPECT is a Medically Recognized Brain Diagnostic Technology
Select the indications for brain SPECT
Describe the limitations of brain SPECT
Assess if SPECT is appropriate for the evaluation of TBI
Target Audience:
Faculty, Residents
CanMEDS Roles:
Medical Expert, Leader, Professional
Declaration of COI:
No conflicts to declare.
1225-1240
Questions & Discussion
1240-1305
Functional Neurologic Disorders
Anthony Feinstein
My talk with start with a brief historical overview of FND (hysteria), followed by a case report, a summary of brain changes liked to FND and close with
some thoughts on optimal treatment.
At the end of this session, participants will be able to:
Describe the clinical characteristics of FND
Identify the functional brain changes associated with FND
Define how best to manage FND.
Target Audience:
Faculty, Residents
CanMEDS Roles:
Communicator, Scholar, Professional
Declaration of COI:
Speaker’s honorarium from Biogen, Novartis, Sanofi-Genzyme, Roche. Grant support from MS Society of Canada, Bristol Myers Squibb.
1305-1320
Questions & Discussion
1320-1345
Is TBI a Chronic Disease?
Ross Zafonte
Traumatic brain injury has been associated with neurodegenerative disease. This lecture, will help define the existing literature in the domain of
pathology and the association with multiple phenotypes. The discussion will also describe the putative linkage between brain injury and multiple medical
comorbid conditions..
At the end of this session, participants will be able to:
Cite the biologic and epidemiologic data linking brain injury to chronic disease
Assess the strengths and limitations in the linkage between brain injury and chronic disease
Critique the existing literature on chronic brain injury and brain health
Describe the critical pathological and phenotypic factors associated with declines in chronic brain health
Reflect on a plan to distinguish medical comorbids and there contribution to brain health
Target Audience:
Faculty, Residents
CanMEDS Roles:
Medical Expert (the integrating role)
Declaration of COI:
Receipt of honoraria on Scientific Advisory Board from myomo. On Biodirection Scientific Advisory Board. Research for NIH, NIDILRR,
DOD.
1345-1355
Questions & Discussion
1355-1400
Wrap up & Applause
Friday, November 12 (SCI)
1200-1205
Introduction
Hossein Amani
1205-1230
SCI & Bone Health
Cathy Craven
1230-1245
Questions & Discussion
1245-1310
Intrathecal Baclofen For Generalized Spasticity: An Overview And Update For 2021
Anthony Burns
Target Audience:
Faculty, Residents, Medical Students
CanMEDS Roles:
Medical Expert (the integrating role), Scholar, Professional
1310-1325
Questions & Discussion
1325-1345
Botulin Toxin (Bowel & Bladder)
Sender Herschorn
1345-1355
Questions & Discussion
1355-1400
Wrap up & Applause
Saturday, November 13 (ALS/MS & Cancer)
1200-1205
Introduction
Larry Robinson
1205-1230
ALS Update
Lorne Zinman
The session will provide an update on the latest ALS diagnostic criteria, management and research developments.
At the end of this session, participants will be able to:
Describe the latest ALS diagnostic criteria and management
Target Audience:
Faculty, Residents,
CanMEDS Roles:
Medical Expert (the integrating role), Communicator, Collaborator, Leader, Scholar
1230-1245
Questions & Discussion
1245-1310
Advanced Wound Care 101
Morty Eisenberg
A review of fundamental principles used to manage wounds appropriately, based on best practice recommendations.
At the end of this session, participants will be able to:
Describe the wound healing paradigm, as a strategy for managing wounds
List the components of local wound care
Discuss the principles of moist wound healing in choosing appropriate dressings
Target Audience:
Faculty, Residents, Medical Students, nurses
CanMEDS Roles:
Medical Expert (the integrating role), Communicator, Collaborator
1310-1325
Questions & Discussion
1325-1345
Targeted Muscle Reinnervation Surgery
Amanda Mayo
Targeted Muscle Reinnervation surgery for upper and lower extremity amputations. A review of the procedure, initially established for enhanced
myoelectric control and more recently for neuroma and phantom limb prevention and management.
At the end of this session, participants will be able to:
Identify potential limb loss patients that may benefit from TMR
Describe benefits of TMR for function and pain management post limb loss
Target Audience:
Faculty, Residents, Medical Students
CanMEDS Roles:
Medical Expert (the integrating role), Collaborator